NCI Launches Molecular Medicine Clinical Trials; Response Genetics Nabs Profiling Contract | GenomeWeb

NEW YORK (GenomeWeb) – The National Cancer Institute said today it has launched new clinical trials that will use tumor sequencing and genetic markers to help determine whether therapies targeting genetic alterations can prevent lung cancer recurrence.

Separately, Response Genetics said it has been awarded a "multi-million dollar" subcontract from Leidos Biomedical Research, a contractor for the NCI-sponsored Frederick National Laboratory for Cancer Research, to handle molecular profiling for the trials. Further details about the subcontract's terms were not immediately available.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.